Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof

A compound represented by Formula VI or Formula VII:

• or a pharmaceutically acceptable salt, a stereoisomer, and/or an N-oxide thereof, wherein:
• R3 is selected from the group consisting of hydrogen, —C1-C6alkyl, —C(O)—R31, and —C(O)—O—R32;
• R31 is selected from the group consisting of hydrogen, —C1-C6alkyl;
• —C1-C6haloalkyl, —C3-C6cycloalkyl, and phenyl;
• R32 is selected from the group consisting of hydrogen, —C1-C6alkyl;
• —C1-C6haloalkyl, —C3-C6cycloalkyl, and phenyl;
• R10 and R11 for each occurrence are independently selected from the group consisting of hydrogen, halogen, —OH, —C1-C6alkyl, —C1-C6alkoxy, —CO2H, or —NR′R′, wherein R′ for each occurrence is independently selected from hydrogen and, —C1-C6 alkyl;
• and
• R12 and R13 for each occurrence are independently selected from the group consisting of hydrogen and —C1-C6 alkyl;
• or R13 and R12 together with the nitrogen to which they are bound form a 4-6 membered heterocycle;
• and wherein C1-C6 alkyl is optionally for each occurrence substituted by one, two, or three substituents each selected from the group consisting of halogen, hydroxyl, and amino.

A compound represented by Formula IX or Formula X:

• or a pharmaceutically acceptable salt, a stereoisomer, and/or an N-oxide thereof, wherein:
• R1 and R2 are independently selected from the group consisting of hydrogen, —C1-C6alkyl, —C(O)—C1-C6alkyl, and —C(O)—O—C1-C6alkyl;
• or R1 and R2 taken together with the nitrogen to which they are attached form a 4-6 membered heterocyclic ring;
• R3 is selected from the group consisting of hydrogen, —C1-C6alkyl, —C(O)—R31, and —C(O)—O—R32;
• R31 is selected from the group consisting of hydrogen, —C1-C6alkyl;
• —C1-C6haloalkyl, —C3-C6cycloalkyl, and phenyl;
• R32 is selected from the group consisting of hydrogen, —C1-C6alkyl;
• —C1-C6haloalkyl, —C3-C6cycloalkyl, and phenyl;
• R4 is selected from the group consisting of hydrogen, —C1-C6alkyl, —C(O)—C1-C6alkyl, —C(O)—O—C1-C6alkyl, and —O—CH2-phenyl;
• wherein any aforementioned C1-C6alkyl, independently for each occurrence, is optionally substituted by one, two or three substituents each independently selected from —C(O)NRaRb, —NRaRb, hydroxyl, —SH, phenyl, —O—CH2-phenyl, and halogen;
• and any aforementioned phenyl, independently for each occurrence, is optionally substituted by one, two or three substituents each independently selected from —C(O)NRaRb, —NRaRb, —C1-C3alkoxy, hydroxyl, and halogen;
• Ra and Rb are each independently for each occurrence selected from the group consisting of hydrogen, —C(O)—O—CH2-phenyl, and —C1-C3alkyl;
• or Ra and Rb taken together with the nitrogen to which they are attached form a 4-6 membered heterocyclic ring;
• R5, R6, R7 and R8 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, phenyl, amido, amino, C1-4alkyl, C2-4alkenyl, —NH—C(O)—C1-6alkyl, —NH—C(O)—C1-6alkylene-phenyl, —NH—C(O)—O—C1-6alkyl, and —NH—C(O)—O—C1-6alkylene-phenyl;
• wherein C1-4alkyl and phenyl are optionally substituted by one or more substituents selected from RP;
• or
• R6 and R7 taken together with the adjacent carbons to which they are attached form a 3-membered carbocyclic ring which is optionally substituted by one or two substituents independently selected from the group consisting of halogen, hydroxyl, —C1-C3alkyl, —C1-C3alkoxy, —C(O)NRaRb, and —NRaRb;
• RP is selected, independently for each occurrence, from the group consisting of carboxy, hydroxyl, halogen, amino, phenyl, C1-6alkoxy, and C1-3alkyl optionally substituted by one or more substituents independently selected from the group consisting of halogen, hydroxyl and amino;
• R9 and R10 are each independently selected from the group consisting of hydrogen and —C1-C3alkyl, or R9 and R10 taken together form an oxo moiety;
• and
• m is 0 or 1.